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Abstract
Leptomeningeal carcinomatosis is a rare complication of several types of cancer. 
There are many possible clinical features, and the diagnosis is made with brain imag-
ing and cytological analysis of cerebrospinal fluid. Treatment is widely debated and, 
concerning overall survival, there does not seem to exist a treatment option which is 
definitely superior. The present work describes the case of a 53-year-old man diag-
nosed with leptomeningeal carcinomatosis secondary to lung adenocarcinoma, who 
was treated with whole brain radiation therapy and, upon relapse, with intrathecal 
chemotherapy, showing both an above-average overall survival and a high perfor-
mance status.
Resumo
A carcinomatose leptomeníngea é uma complicação rara de alguns tipos de neo-
plasia. As manifestações clínicas possíveis são várias, sendo o diagnóstico feito por 
meios imagiológicos e análise citológica do líquido cefalorraquidiano. O tratamento 
é um motivo de debate, pois não parece existir uma opção de tratamento que seja 
claramente superior, no que toca à sobrevida. Este estudo de caso descreve o caso 
de um homem de 53 anos diagnosticado com carcinomatose leptomeníngea secun-
dária a adenocarcinoma do pulmão, que foi tratado com radioterapia holocraniana 
e, aquando da recidiva, quimioterapia intratecal, revelando tanto uma sobrevida 
como um estado funcional acima da média.
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CASO CLÍNICO/CASE REPORT
Leptomeningeal Carcinomatosis in a Patient with Lung Adenocarcinoma 
Treated with Whole Brain Radiation Therapy and Intrathecal Chemotherapy
Carcinomatose Leptomeníngea num Doente com Adenocarcinoma do Pulmão Tratada 
com Radioterapia Holocraniana e Quimioterapia Intratecal
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Introduction 
The central nervous system is a possible site where 
distant spread occurs for certain types of cancer. Lep-
tomeningeal metastasis are a rare complication, albeit 
with a rising incidence and a bad prognosis.1 The increas-
ing incidence can be explained by a number of factors, 
such as improvement in systemic control of the primary 
cancer, which leads to improved survival, improvements 
in imaging and diagnostic accuracy and also the use of 
chemotherapeutic agents that do not cross the blood-
brain barrier.2 The most frequently associated solid 
cancers are, in descending order of frequency, breast 
adenocarcinoma, lung adenocarcinoma and malignant 
melanoma. However, leukemia and lymphoma are the 
most frequent causes of leptomeningeal metastasis.1
The clinical manifestations of meningeal involvement 
are varied, and they are caused by an increase in intrac-
ranial pressure (ICP), infiltration or compression of the 
brain parenchyma, disruption of the blood-brain barrier, 
among others.3 Of note, one of the signs of increased 
ICP is the presence of plateau wave phenomena, which 
are acute elevations of ICP which translate clinically 
into paroxysmal neurological symptoms triggered by 
postural changes.4 Other characteristic symptoms and 
signs of meningeal involvement include headache, gait 
disorders (apraxia or ataxia), cognitive impairment, loss 
of consciousness (usually due to seizures), cranial nerve 
dysfunction or spinal nerve root compromise.3
Before magnetic resonance imaging (MRI), the gold 
standard for the diagnosis of leptomeningeal carcinoma-
tosis was cerebrospinal fluid (CSF) cytology.5 Although it 
is still important and required for a confirmed diagnosis, 
MRI has become fundamental.6 Moreover, the combina-
tion of clinical features and suggestive imaging features is 
sufficient for a probable diagnosis, even with a negative 
CSF cytology.7 However, the use of MRI has no prog-
nostic impact, and a positive CSF cytology is sufficient 
for diagnosis even with a normal MRI.5,6 In rare cases, 
18F-fluorodeoxyglucose positron emission tomography 
(FDG-PET) can be useful for the diagnosis.8
Leptomeningeal metastasis can be classified into two 
types: type 1, in case the diagnosis is confirmed by posi-
tive CSF cytology or biopsy; type 2, in case the diagnosis 
is made using only clinical and imaging features.6
There is a wide therapeutic arsenal for the treatment 
of this condition, including optimization of the treat-
ment of the primary cancer, whole brain radiation ther-
apy (WBRT) or focal radiation therapy and intrathecal 
chemotherapy (ITC).9 The efficacy of these treatments 
is controversial, and there exists data which supports 
the preferential use of several of these options.9,10 How-
ever, the role of WBRT is becoming less important.11 
EANO-ESMO guidelines recommend patient stratifica-
tion and therapeutic decision according to prognosis, 
the type of meningeal metastasis, the presence of ac-
tive cerebral metastasis and the status of the primary 
cancer; however, the level of evidence for therapeutic 
recommendations is low and the therapeutic decision 
must always be individually tailored.6,11
Life expectancy after the diagnosis of leptomeningeal 
metastasis depends on the primary cancer. The median 
overall survival of non-small cell lung cancer leptomenin-
geal metastasis is 3 to 8.7 months.9
This report describes a csase of leptomeningeal car-
cinomatosis secondary to lung adenocarcinoma, treated 
successfully with WBRT and, upon relapse, ITC.
Case Report
In September 2019, a 53-year-old male went to 
the ED of Instituto Português de Oncologia de Lisboa 
Francisco Gentil complaining of severe holocranial 
headache, which woke the patient up from sleep, loss 
of visual acuity, scintillating scotomata and loss of bal-
ance, with a 1-week evolution period. There were no 
significant findings on neurological examination. He un-
derwent a head computerized tomography (CT) scan, 
which showed nonacute ischemic lesions in the poste-
rior fossa, which would not explain the clinical picture. 
However, the previous records of the patient showed a 
CT scan from 2010, which did not show these findings. 
There was also a slight supratentorial ventriculomegaly 
in relation to this previous exam.
The patient had a history of adenocarcinoma of the 
lower lobe of the right lung, which was diagnosed in 
December 2010 by transthoracic biopsy (cT3N0M0), 
and he underwent lobectomy in January 2011, leading 
to the definitive diagnosis of mixed adenocarcinoma (in-
vasive adenocarcinoma with areas of bronchioloalveolar 
adenocarcinoma), pT3N2M0. Genetic analysis revealed 
an insertion in exon 20 of the EGFR gene (a mutation 
which confers resistance to tyrosine kinase inhibitors) 
and wild-type ALK and PDL1 genes. Adjuvant chemora-
diotherapy was given, with carboplatin and paclitaxel 
until May 2011, and at this point a state of complete 
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remission had been achieved.
In December 2016, in a follow-up appointment, the 
patient complained of sciatic pain and paresthesia along 
the right lower member, and a bony metastasis was 
suspected in L5, which was confirmed in January 2017 
by biopsy of the lesion shown in a CT scan. The biopsy 
showed a histological and genetic profile compatible 
with a metastasis of lung adenocarcinoma. The patient 
underwent single-dose external radiation therapy in 
March 2017, with complete response, which was docu-
mented in a positron emission tomography (PET) scan 
at two times: March 2017 and January 2018.
In July 2018, an increase in the number of pulmonary 
nodules in the left superior lobe was documented, as 
well as the appearance of de novo bilateral micronod-
ules, which raised suspicion for progression of the neo-
plastic process. This motivated hospital admission for 
treatment with cisplatin and pemetrexed, with radio-
logically documented improvement.
In May 2019, a lumbar spine CT scan revealed a pro-
gression of the metastatic lesion of L5, with a patho-
logic fracture and compromise of the root of the right 
S1 nerve. Therefore, the patient underwent a second 
round of single-dose 20 Gy external radiation therapy, 
with clinical improvement.
Following the described episode from September 
2019, we admitted the patient to the ward, and he un-
derwent a head MRI, which showed aspects suggestive 
of leptomeningeal dissemination of the primary cancer, 
namely an effacement of the cerebral gyri in the left 
frontoparietal convexity, with FLAIR hyperintensity in 
the sulci (Fig. 1). Lumbar punctures were performed 
and 10 mL of CSF were collected, and on the second 
attempt, neoplastic cells positive for TTF-1 were found 
on cytological analysis (Fig. 2). Given the genetic pro-
file, which excluded the patient from receiving targeted 
therapy, he underwent WBRT (30 Gy) and was treated 
with dexamethasone, and the follow-up MRI in Febru-
ary 2020 did not reveal aspects of meningeal disease.
In follow-up appointments, the patient complained 
of worsening of symptoms in May 2020, with sudden 
onset lipothymia upon standing up and visual distur-
bances in the right hemifields, which raised suspicion for 
plateau wave phenomena. On fundoscopy, there was 
slight bilateral papilledema. Given the apparent progres-
sion of the meningeal disease, the patient was started 
on acetazolamide and underwent head and neuroaxis 
MRI, to document the progression of the disease, and 
a cisternography with 99m Tc-DTPA to identify pos-
sible blockages in CSF circulation and verify eligibility 
for intrathecal chemotherapy. The MRI showed once 
again signs of leptomeningeal involvement, with some 
gadolinium-enhancing areas and FLAIR hyperintensities, 
as well as a slight ventriculomegaly. The cisternography 
showed normal CSF circulation. The lumbar puncture 
previous to this exam showed an opening pressure of 
15.5 cmH2O, a protein concentration of 67 mg/dL and 
no neoplastic cells on cytology. The neurological exam 
upon admission showed slight impairment of episodic 
memory, partial bilateral loss of visual acuity, bilateral 
papilledema and hemorrhages around the optic disc, 
more intense in the right eye. The patient also had a 
Figure 2. CSF immunohistochemistry with TTF1-positive 
cells.
Figure 1. FLAIR imaging showing slight hyperintensity of 
the left hemisphere frontal sulci.
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mild ataxic gait. We treated the patient with 30 mg of 
intrathecal cytarabine, twice per week for one month. 
After treatment, there was clinical improvement, with 
lowering of headache intensity and frequency of plateau 
wave phenomena. The patient was discharged and a 
treatment plan of continuation of intrathecal chemo-
therapy was devised. In September 2020, the patient 
had a survival time of 12 months since the diagnosis of 
leptomeningeal carcinomatosis and a Karnofsky perfor-
mance scale of 80.
Discussion
 Leptomeningeal carcinomatosis is still a disease with 
a bad prognosis. Although rare, the incidence is grow-
ing. Normally it has a very aggressive clinical course 
but some patients have a more insidious progression, 
such as our patient. A high level of suspicion is needed 
in symptomatic cancer patients, and as our case clearly 
shows there is opportunity for meaningful therapeutic 
interventions. As such, the recognition of this clinical 
entity is fundamental. The studies that were conducted 
regarding treatment are not consensual in which is the 
best therapeutic option for every situation, and more 
research is necessary in this area. 
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